Otsuka Holdings Co., Ltd. (OTSKY)
USD 27.55
(-0.4%)
USD 27.55
(-0.4%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1267.73 Billion JPY | 13.51% |
| 2022 | 982.43 Billion JPY | 15.47% |
| 2021 | 850.77 Billion JPY | 10.28% |
| 2020 | 771.47 Billion JPY | 0.13% |
| 2019 | 770.5 Billion JPY | 1.6% |
| 2018 | 758.36 Billion JPY | 3.52% |
| 2017 | 732.6 Billion JPY | 4.06% |
| 2016 | 704.04 Billion JPY | -16.59% |
| 2015 | 844.11 Billion JPY | -8.72% |
| 2014 | 924.77 Billion JPY | 41.28% |
| 2013 | 654.56 Billion JPY | 44.55% |
| 2012 | 452.82 Billion JPY | 1.36% |
| 2011 | 446.73 Billion JPY | -4.17% |
| 2010 | 466.17 Billion JPY | 17.97% |
| 2009 | 395.15 Billion JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 311.53 Billion JPY | 8.88% |
| 2024 Q1 | 286.13 Billion JPY | -11.36% |
| 2023 Q4 | 322.79 Billion JPY | 14.79% |
| 2023 Q1 | 240.21 Billion JPY | -15.77% |
| 2023 Q2 | 269.59 Billion JPY | 12.23% |
| 2023 Q3 | 281.21 Billion JPY | 4.31% |
| 2023 FY | 1115.15 Billion JPY | 13.51% |
| 2022 Q3 | 246.01 Billion JPY | 2.72% |
| 2022 Q4 | 285.18 Billion JPY | 15.92% |
| 2022 FY | 982.43 Billion JPY | 15.47% |
| 2022 Q1 | 211.73 Billion JPY | -17.47% |
| 2022 Q2 | 239.5 Billion JPY | 13.12% |
| 2021 FY | 850.77 Billion JPY | 10.28% |
| 2021 Q3 | 215.44 Billion JPY | 9.26% |
| 2021 Q4 | 256.56 Billion JPY | 19.09% |
| 2021 Q2 | 197.17 Billion JPY | 8.59% |
| 2021 Q1 | 181.58 Billion JPY | -16.15% |
| 2020 Q3 | 183.42 Billion JPY | -1.89% |
| 2020 Q2 | 186.94 Billion JPY | 1.31% |
| 2020 FY | 771.47 Billion JPY | 0.13% |
| 2020 Q1 | 184.53 Billion JPY | -14.04% |
| 2020 Q4 | 216.56 Billion JPY | 18.07% |
| 2019 Q3 | 189.85 Billion JPY | 2.87% |
| 2019 FY | 770.5 Billion JPY | 1.6% |
| 2019 Q4 | 214.68 Billion JPY | 13.08% |
| 2019 Q2 | 184.56 Billion JPY | 1.74% |
| 2019 Q1 | 181.4 Billion JPY | -16.45% |
| 2018 Q3 | 202.99 Billion JPY | 16.05% |
| 2018 Q2 | 174.92 Billion JPY | 7.1% |
| 2018 Q4 | 217.11 Billion JPY | 6.95% |
| 2018 FY | 758.36 Billion JPY | 3.52% |
| 2018 Q1 | 163.32 Billion JPY | -19.03% |
| 2017 Q3 | 174.57 Billion JPY | -11.56% |
| 2017 FY | 732.6 Billion JPY | 4.06% |
| 2017 Q4 | 201.7 Billion JPY | 15.54% |
| 2017 Q2 | 197.39 Billion JPY | 24.21% |
| 2017 Q1 | 158.92 Billion JPY | -24.13% |
| 2016 Q2 | 162.6 Billion JPY | 0.7% |
| 2016 Q4 | 209.47 Billion JPY | 28.46% |
| 2016 FY | 704.04 Billion JPY | -16.59% |
| 2016 Q3 | 163.06 Billion JPY | 0.28% |
| 2016 Q1 | 161.48 Billion JPY | -26.08% |
| 2015 FY | 844.11 Billion JPY | -8.72% |
| 2015 Q4 | 218.44 Billion JPY | 10.24% |
| 2015 Q3 | 198.15 Billion JPY | -2.67% |
| 2015 Q2 | 203.59 Billion JPY | -9.08% |
| 2015 Q1 | 223.92 Billion JPY | 0.0% |
| 2014 Q2 | 207.71 Billion JPY | -16.68% |
| 2014 Q1 | 249.28 Billion JPY | 30.66% |
| 2014 FY | 924.77 Billion JPY | 41.28% |
| 2014 Q3 | 222.55 Billion JPY | 7.15% |
| 2013 Q1 | 188.58 Billion JPY | -25.73% |
| 2013 Q2 | 174.52 Billion JPY | -7.45% |
| 2013 Q4 | 190.77 Billion JPY | -3.57% |
| 2013 Q3 | 197.83 Billion JPY | 13.35% |
| 2013 FY | 654.56 Billion JPY | 44.55% |
| 2012 Q4 | 253.92 Billion JPY | 127.7% |
| 2012 FY | 452.82 Billion JPY | 1.36% |
| 2012 Q3 | 111.51 Billion JPY | 10.92% |
| 2012 Q2 | 100.53 Billion JPY | -24.16% |
| 2012 Q1 | 132.56 Billion JPY | 28.45% |
| 2011 Q3 | 112.44 Billion JPY | 7.49% |
| 2011 Q4 | 103.2 Billion JPY | -8.21% |
| 2011 Q2 | 104.6 Billion JPY | -12.4% |
| 2011 Q1 | 119.41 Billion JPY | 14.48% |
| 2011 FY | 446.73 Billion JPY | -4.17% |
| 2010 Q4 | 104.31 Billion JPY | -8.68% |
| 2010 Q1 | 140.1 Billion JPY | 31.1% |
| 2010 Q2 | 108.78 Billion JPY | -22.35% |
| 2010 Q3 | 114.22 Billion JPY | 5.0% |
| 2010 FY | 466.17 Billion JPY | 17.97% |
| 2009 Q2 | 104.75 Billion JPY | 0.0% |
| 2009 Q4 | 106.86 Billion JPY | -6.64% |
| 2009 Q3 | 114.46 Billion JPY | 9.27% |
| 2009 FY | 395.15 Billion JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AstraZeneca PLC | 29.57 Billion USD | -4186.081% |
| Bristol-Myers Squibb Company PFD CONV 2 | 17.07 Billion USD | -7326.261% |
| CSPC Pharmaceutical Group Limited | 2.14 Billion USD | -58947.953% |
| Clarus Therapeutics Holdings, Inc. | 50.96 Million USD | -2487170.694% |
| Novartis AG | 24.87 Billion USD | -4997.25% |
| PT Kalbe Farma Tbk. | 11823.24 Billion USD | 89.278% |